logo-loader

Medgenics CEO says a number of factors set the company at beneficial "tipping point"

Published: 08:34 06 Jul 2012 BST

Dr Andy Pearlman, President CEO and Founder of Medgenics (AMEX:MDGN LON:MEDG), tells Proactiveinvestors that a number of things have come together: first validation of the clinical trial of EPODURE for the treatment of Sustained Anemia in Dialysis Patients, having been pushed by the US Food & Drug Administration straight into Phase II trials for its"biopump", it shows that the technology is safe and has "tremendous clinical benefit", second is the approval in Israel for a similar trial and then the attainment for a trial for MDGN's hepatitis biopump treatment. Andy also says that the appointment of Dr Sol Barer as Chairman of the board is excellent news. He says one cannot imagine a more "accomplished, famous and sought after leader in the biotechnology world" having started Celgene and building it up into a $25bln company.

Chesnara reports strong 2023 results with improved cash generation and...

Chesnara PLC (LSE:CSN) chief executive Steve Murray discusses the company's full-year results for 2023 with Proactive's Stephen Gunnion, describing them as strong and particularly highlighting £53 million in commercial cash generation and a dividend coverage of around 150%. The company has...

1 hour, 18 minutes ago